Concepedia

Emma Rousseau

ER

Statistics

Publications

10

Citations

586

H-Index

10

Active since

2006

Affiliations

Arvinas (United States)(Current)

Gilead Sciences (United States)

Shanxi Agricultural University

University of Chicago

Emma Rousseau is an author at Arvinas (United States) specializing in medicine, pharmacology, and cell biology.

ORCID

Top concepts

Publications per year

2006–2024

10

Publications

10

Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer

JJ Flanagan, Yimin Qian, SM Gough et al. · Cancer Research · 2019 · 130 citations

, , +20

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 120 citations · Full text

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Jennifer Cantley, Xiaofen Ye, Emma Rousseau et al. · Nature Communications · 2022 · 115 citations · Full text

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 105 citations

, , +20

Genetic network and pathway analysis of differentially expressed proteins during critical cellular events in fracture repair

Xinmin Li, Hali Wang, Edward Touma et al. · Journal of Cellular Biochemistry · 2006 · 26 citations

1–5 of 10